Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients

Table 2

Correlations of sRAGE with baseline characteristics of patients included in the study analyzed as a whole group and after classification according to the dialytic treatment.

sRAGE	All patients	HD	PD
	r	r	r
Age (years)	0.073°	0.031	0.001°
Albumin [g/dL]	−0.071°	−0.108	−0.134
ALT [UI/l]	−0.029°	0.064°	0.094°
AST [UI/l]	−0.077°	−0.163°	0.135°
BMI (kg/m^2)	−0.010°	0.146°	−0.037
BNP [pg/mL]	0.353 °	0.281 °	0.334 °
Creatinine [mg/dL]	0.077	0.060°	0.067
CRP [mg/L]	0.006°	0.156°	−0.241 °
Glucose [mg/dL]	−0.049°	−0.081°	−0.075°
HDL-cholesterol [mg/dL]	−0.019°	−0.200°	0.113°
LDL-cholesterol [mg/dL]	−0.365	−0.433	−0.210
Total cholesterol [mg/dL]	−0.339	−0.456	−0.130
Total protein [g/dL]	−0.056	−0.133°	−0.070
Triglycerides [mg/dL]	−0.127°	−0.111°	−0.069°
Uric acid [mg/dL]	0.087	0.115	−0.067
Urea [mg/dL]	−0.115	0.067	−0.196

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BNP, brain natriuretic peptide; CRP, C-reactive protein; HD, hemodyalisis; PD, peritoneal dialysis; sRAGE, soluble receptor for advanced glycation end products. Correlations were evaluated with Spearman’s (°) or Pearson’s correlation coefficient, as appropriate. ; ; .